Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Revenue projections:

Revenue projections for ASTRAZEN
Revenue projections for ASTRAZEN



Financial Ratios:

currentRatio 1.90900
forwardPE 0.00000
debtToEquity 4.63800
earningsGrowth 0.47600
revenueGrowth 0.25400
grossMargins 0.43553
operatingMargins 0.14467
trailingEps 45.96000
forwardEps 0.00000

ASTRAZEN's current ratio of 1.909 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that ASTRAZEN is financially well-prepared to meet its liabilities without difficulty.
ASTRAZEN's positive earnings and revenue growth suggest that the company is poised for business expansion. This financial strength indicates that ASTRAZEN is expected to continue growing, with rising profits and sales contributing to its long-term success.